These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 3447890)

  • 21. Perspectives on the risk assessment for nongenotoxic carcinogens and tumor promoters.
    Perera FP
    Environ Health Perspect; 1991 Aug; 94():231-5. PubMed ID: 1954932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Possible role of genetic predisposition in multigeneration carcinogenesis.
    Mohr U; Emura M; Aufderheide M; Riebe M; Ernst H
    IARC Sci Publ; 1989; (96):93-103. PubMed ID: 2680958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of promoters on incidence of bladder cancer in experimental animal models.
    Hicks RM
    Environ Health Perspect; 1983 Apr; 50():37-49. PubMed ID: 6873029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Consideration of non-linear, non-threshold and threshold approaches for assessing the carcinogenicity of oral exposure to hexavalent chromium.
    Haney J
    Regul Toxicol Pharmacol; 2015 Dec; 73(3):834-52. PubMed ID: 26493004
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cancer risk assessment of direct acting carcinogens.
    Zito R
    J Exp Clin Cancer Res; 1999 Sep; 18(3):273-8. PubMed ID: 10606168
    [No Abstract]   [Full Text] [Related]  

  • 26. Approach to risk assessment for genotoxic carcinogens based on data from the mouse skin initiation-promotion model.
    Burns F; Albert R; Altshuler B; Morris E
    Environ Health Perspect; 1983 Apr; 50():309-20. PubMed ID: 6873021
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of the effects of promoting agents on liver and urinary bladder carcinogenesis in rats.
    Ito N; Tatematsu M; Nakanishi K; Tsuda H
    Carcinog Compr Surv; 1982; 7():133-7. PubMed ID: 7066916
    [No Abstract]   [Full Text] [Related]  

  • 28. Co-carcinogenesis.
    Clayson DB
    Acta Pharmacol Toxicol (Copenh); 1984; 55 Suppl 2():35-51. PubMed ID: 6385621
    [No Abstract]   [Full Text] [Related]  

  • 29. Incorporating additional biological phenomena into two-stage cancer models.
    Sielken RL; Bretzlaff RS; Stevenson DE
    Prog Clin Biol Res; 1994; 387():237-60. PubMed ID: 7972250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thresholds of carcinogenicity in the ED01 study.
    Andersen ME; Conolly RB; Gaylor DW
    Toxicol Sci; 2003 Aug; 74(2):486-7; author reply 487-8. PubMed ID: 12874369
    [No Abstract]   [Full Text] [Related]  

  • 31. Synergistic effects of N-nitroso compounds in experimental long-term carcinogenesis studies.
    Habs M; Schmähl D
    Oncology; 1980; 37(4):259-65. PubMed ID: 7443158
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nonlinearity of dose-response functions for carcinogenicity.
    Hoel DG; Portier CJ
    Environ Health Perspect; 1994 Jan; 102 Suppl 1(Suppl 1):109-13. PubMed ID: 8187698
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the form of the cell growth rate function of the two-stage model for carcinogenesis.
    Charnley G; Wilson JD
    Prog Clin Biol Res; 1991; 369():291-301. PubMed ID: 1946526
    [No Abstract]   [Full Text] [Related]  

  • 34. The assessment of low-dose carcinogenicity.
    Armitage P
    Biometrics; 1982 Mar; 38 Suppl():119-39. PubMed ID: 7046818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A search for thresholds and other nonlinearities in the relationship between hexavalent chromium and lung cancer.
    Park RM; Stayner LT
    Risk Anal; 2006 Feb; 26(1):79-88. PubMed ID: 16492182
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined effect of multiple carcinogens and synergy index.
    Kawaguchi I; Doi M; Kakinuma S; Shimada Y
    J Theor Biol; 2006 Nov; 243(1):143-51. PubMed ID: 16860345
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multistage models of carcinogenesis.
    Armitage P
    Environ Health Perspect; 1985 Nov; 63():195-201. PubMed ID: 3908088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The linearized multistage model and the future of quantitative risk assessment.
    Crump KS
    Hum Exp Toxicol; 1996 Oct; 15(10):787-98. PubMed ID: 8906427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of non-mammalian species in bioassays for carcinogenicity.
    Bunton TE
    IARC Sci Publ; 1999; (146):151-84. PubMed ID: 10353387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of animal carcinogenicity experiments with multiple tumor types.
    Lu Y; Malani HM
    Biometrics; 1995 Mar; 51(1):73-86. PubMed ID: 7766797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.